Hormone replacement therapy and breast cancer: A qualitative review

Trudy L. Bush, M. Whiteman, J. A. Flaws

Research output: Contribution to journalReview article

Abstract

OBJECTIVE: To assess whether recent epidemiologic evidence supports an association between use of estrogen replacement therapy or hormone replacement therapy and risk of breast cancer. DATA SOURCES: The keywords "estrogen," "estrogen replacement therapy," or "hormone replacement therapy," and "breast cancer" or "breast neoplasm," were used to search for articles published from 1975-2000 in MEDLINE and Dialogweb. Only articles published in peer-reviewed journals and containing original data were included in this review. METHODS: Unadjusted or age-adjusted risk estimates for breast cancer among ever users of estrogen therapy compared with never users were abstracted from published articles or calculated using the data provided in the published reports. TABULATION, INTEGRATION, AND RESULTS: We found little consistency among studies that estimated the risk of breast cancer in hormone users compared with nonusers and in studies assessing the risk by duration of use. However, there was consistently a lower risk of death from breast cancer in hormone users compared with nonusers. CONCLUSION: The evidence did not support the hypotheses that estrogen use increases the risk of breast cancer and that combined hormone therapy increases the risk more than estrogen only. Additional observational studies are unlikely to alter this conclusion. Although a small increase in breast cancer risk with hormone therapy or an increased risk with long duration of use (15 years or more) cannot be ruled out, the likelihood of this must be small, given the large number of studies conducted to date.

Original languageEnglish (US)
Pages (from-to)498-508
Number of pages11
JournalObstetrics and Gynecology
Volume98
Issue number3
DOIs
StatePublished - Oct 3 2001
Externally publishedYes

Fingerprint

Hormone Replacement Therapy
Breast Neoplasms
Estrogens
Hormones
Estrogen Replacement Therapy
MEDLINE
Observational Studies
Therapeutics

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Hormone replacement therapy and breast cancer : A qualitative review. / Bush, Trudy L.; Whiteman, M.; Flaws, J. A.

In: Obstetrics and Gynecology, Vol. 98, No. 3, 03.10.2001, p. 498-508.

Research output: Contribution to journalReview article

Bush, Trudy L. ; Whiteman, M. ; Flaws, J. A. / Hormone replacement therapy and breast cancer : A qualitative review. In: Obstetrics and Gynecology. 2001 ; Vol. 98, No. 3. pp. 498-508.
@article{6bdb0b9795f04205a35b4b7d35b67429,
title = "Hormone replacement therapy and breast cancer: A qualitative review",
abstract = "OBJECTIVE: To assess whether recent epidemiologic evidence supports an association between use of estrogen replacement therapy or hormone replacement therapy and risk of breast cancer. DATA SOURCES: The keywords {"}estrogen,{"} {"}estrogen replacement therapy,{"} or {"}hormone replacement therapy,{"} and {"}breast cancer{"} or {"}breast neoplasm,{"} were used to search for articles published from 1975-2000 in MEDLINE and Dialogweb. Only articles published in peer-reviewed journals and containing original data were included in this review. METHODS: Unadjusted or age-adjusted risk estimates for breast cancer among ever users of estrogen therapy compared with never users were abstracted from published articles or calculated using the data provided in the published reports. TABULATION, INTEGRATION, AND RESULTS: We found little consistency among studies that estimated the risk of breast cancer in hormone users compared with nonusers and in studies assessing the risk by duration of use. However, there was consistently a lower risk of death from breast cancer in hormone users compared with nonusers. CONCLUSION: The evidence did not support the hypotheses that estrogen use increases the risk of breast cancer and that combined hormone therapy increases the risk more than estrogen only. Additional observational studies are unlikely to alter this conclusion. Although a small increase in breast cancer risk with hormone therapy or an increased risk with long duration of use (15 years or more) cannot be ruled out, the likelihood of this must be small, given the large number of studies conducted to date.",
author = "Bush, {Trudy L.} and M. Whiteman and Flaws, {J. A.}",
year = "2001",
month = "10",
day = "3",
doi = "10.1016/S0029-7844(01)01453-3",
language = "English (US)",
volume = "98",
pages = "498--508",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Hormone replacement therapy and breast cancer

T2 - A qualitative review

AU - Bush, Trudy L.

AU - Whiteman, M.

AU - Flaws, J. A.

PY - 2001/10/3

Y1 - 2001/10/3

N2 - OBJECTIVE: To assess whether recent epidemiologic evidence supports an association between use of estrogen replacement therapy or hormone replacement therapy and risk of breast cancer. DATA SOURCES: The keywords "estrogen," "estrogen replacement therapy," or "hormone replacement therapy," and "breast cancer" or "breast neoplasm," were used to search for articles published from 1975-2000 in MEDLINE and Dialogweb. Only articles published in peer-reviewed journals and containing original data were included in this review. METHODS: Unadjusted or age-adjusted risk estimates for breast cancer among ever users of estrogen therapy compared with never users were abstracted from published articles or calculated using the data provided in the published reports. TABULATION, INTEGRATION, AND RESULTS: We found little consistency among studies that estimated the risk of breast cancer in hormone users compared with nonusers and in studies assessing the risk by duration of use. However, there was consistently a lower risk of death from breast cancer in hormone users compared with nonusers. CONCLUSION: The evidence did not support the hypotheses that estrogen use increases the risk of breast cancer and that combined hormone therapy increases the risk more than estrogen only. Additional observational studies are unlikely to alter this conclusion. Although a small increase in breast cancer risk with hormone therapy or an increased risk with long duration of use (15 years or more) cannot be ruled out, the likelihood of this must be small, given the large number of studies conducted to date.

AB - OBJECTIVE: To assess whether recent epidemiologic evidence supports an association between use of estrogen replacement therapy or hormone replacement therapy and risk of breast cancer. DATA SOURCES: The keywords "estrogen," "estrogen replacement therapy," or "hormone replacement therapy," and "breast cancer" or "breast neoplasm," were used to search for articles published from 1975-2000 in MEDLINE and Dialogweb. Only articles published in peer-reviewed journals and containing original data were included in this review. METHODS: Unadjusted or age-adjusted risk estimates for breast cancer among ever users of estrogen therapy compared with never users were abstracted from published articles or calculated using the data provided in the published reports. TABULATION, INTEGRATION, AND RESULTS: We found little consistency among studies that estimated the risk of breast cancer in hormone users compared with nonusers and in studies assessing the risk by duration of use. However, there was consistently a lower risk of death from breast cancer in hormone users compared with nonusers. CONCLUSION: The evidence did not support the hypotheses that estrogen use increases the risk of breast cancer and that combined hormone therapy increases the risk more than estrogen only. Additional observational studies are unlikely to alter this conclusion. Although a small increase in breast cancer risk with hormone therapy or an increased risk with long duration of use (15 years or more) cannot be ruled out, the likelihood of this must be small, given the large number of studies conducted to date.

UR - http://www.scopus.com/inward/record.url?scp=0034825795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034825795&partnerID=8YFLogxK

U2 - 10.1016/S0029-7844(01)01453-3

DO - 10.1016/S0029-7844(01)01453-3

M3 - Review article

C2 - 11530137

AN - SCOPUS:0034825795

VL - 98

SP - 498

EP - 508

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 3

ER -